查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1992559

异体干细胞市场：2026-2032年全球市场预测（按组织类型、应用、来源、产品类型、最终用户和分销管道划分）

Allogeneic Stem Cells Market by Tissue Type, Application, Source, Product Type, End-User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，异体干细胞市场价值将达到 3.9314 亿美元，到 2026 年将成长至 4.7137 亿美元，到 2032 年将达到 13.654 亿美元，复合年增长率为 19.46%。

主要市场统计数据
基准年 2025 3.9314亿美元
预计年份：2026年 4.7137亿美元
预测年份 2032 13.654亿美元
复合年增长率 (%) 19.46%

一份着重分析异体干细胞治疗发展趋势的报告，为领导者提供了临床潜力、生产现状和策略决策因素的框架。

异体干细胞疗法利用捐赠者来源的细胞治疗多种疾病，正从概念阶段迈向临床应用阶段。细胞取得、免疫调节和可扩展生产技术的进步，以及不断完善的法律规范，正重新激发生物製药公司、契约製造和临床服务供应商的兴趣。与自体疗法相比，异体干细胞治疗方法具有明显的优势，包括现成可用、剂量标准化以及规模经济效益，从而降低每次治疗的复杂性。

阐明将重塑同种异体细胞疗法的临床路径、生产模式和商业化策略的变革性变化。

在异体干细胞领域，多项变革正在同步发生，重新定义价值创造和竞争优势。临床上，透过多重治疗和联合治疗，供体来源细胞的治疗效用不断拓展；同时，免疫工程和标靶递送技术也不断提升其安全性和有效性。监管方面也与临床发展同步成熟。监管机构正在明确疗效、等效性和上市后监测的指导原则，这降低了研发者的不确定性，并加速了专案风险的降低。

评估美国于 2025 年宣布的关税调整对供应链成本、筹资策略和临床项目的累积影响。

2025年实施的关税调整为异体干细胞开发公司及其生产合作伙伴的全球物流和采购计画带来了新的复杂性。关税带来的成本压力主要影响进口耗材、特殊试剂以及细胞处理和低温保存所需的某些设备，迫使各机构重新评估其供应商组合，并在条件允许的情况下考虑地域多角化筹资策略。这些变化使得供应链韧性成为经营团队的首要任务，因为延误和对单一供应商的依赖会导致临床试验进度延误，并影响患者的治疗。

从组织类型、治疗应用、供应来源、产品形式、最终用户和分销渠道等方面提取细緻的细分信息，以指导产品组合的优先级排序。

有效的细分框架能够识别技术风险、临床机会和商业性可行性之间的交集。在区分组织类型时，造血干细胞（通常来自骨髓或週边血，用于治疗血液系统和免疫系统疾病）与间质干细胞（来自脂肪组织、骨髓和间质干细胞，预期具有免疫调节和再生能力）有所区别。这些组织来源的特性会影响捐赠者选择、生产流程和疗效检测设计，因此需要针对每种组织类型製定相应的开发路径。

阐明美洲、欧洲、中东和非洲以及亚太地区的区域趋势，这些趋势影响着同种异体干细胞疗法的监管方法、製造地和引进途径。

区域差异影响着异体干细胞疗法推广的速度和结构。在美洲，人们越来越重视在法律规范内简化再生医学和先进医疗治疗的途径。此外，健全的临床试验体系和一体化的医院系统也已建立，为早期商业化和真实世界数据（REW）的生成提供了支持。这种环境有利于申办方协调多中心试验，并与保险公司就基于疗效的合约和保险覆盖模式进行谈判。

在同种异体细胞专案中，塑造研发、製造和物流卓越领导力的企业策略行为和竞争原型。

在异体干细胞领域运作的公司可分为不同的类型，每种类型都代表着不同的规模化和价值创造路径。一种类型是垂直整合的研发公司，它们整合了内部研发、製程开发和临床实施，以保护智慧财产权并直接控制关键品质属性。另一种类型包括专业的契约製造组织 (CMO) 和服务供应商，它们为多家研发公司提供可扩展的生产能力、法规支援和技术转移服务，从而缩短那些希望以最小资产投入实现商业化的客户进入临床试验的时间。

行业领导者可以实施的可操作、高优先级建议，以促进专案稳健性、供应弹性、监管准备和市场渗透。

首先，我们将把供应链韧性纳入早期研发决策，具体措施包括：认证多家关键试剂供应商、建立区域采购管道以及维持策略性库存缓衝，以降低关税和清关流程造成的干扰。早期采用双供应商和替代材料策略可以降低依赖单一供应商的风险，并提高专案的连续性。其次，我们将投资模组化和平台化生产方式，以实现快速规模化生产，并柔软性利用通用生产线满足多种适应症的需求。这将提高资本效率，并缩短临床试验的前置作业时间。

对本报告的研究结果所采用的跨学科研究方法进行了透明的解释，该方法结合了原始研究、二手资料整合和专家检验。

本分析的调查方法融合了与主要相关人员的对话、有针对性的文献整合以及反覆的专家验证，以确保获得平衡且切实可行的见解。主要资讯来源包括对临床研究人员、生产经理、供应链专家和监管顾问的结构化检验，这些访谈提供了关于营运限制、临床终点和市场准入趋势的真实观点。这些定性见解与包括同行评审文献、监管指导文件和技术白皮书在内的二级资讯来源进行了交叉比对，以便更好地理解相关趋势和技术进步。

简要概述了为什么整合营运卓越、有针对性的临床重点和策略伙伴关係对于最大限度地发挥同种异体干细胞疗法的潜力至关重要。

异体干细胞领域正处于转折点，科学进步和生产製造创新，结合严谨的商业化策略，将对患者产生深远的影响。仅凭临床潜力并不能保证持续应用。相反，成功需要严谨的转化研究、可重复的生产製造、稳健的供应链以及与积极主动的支付方建立合作关係。能够整合这些能力的机构将更有能力克服监管方面的复杂性，并缩短从临床试验到常规应用的路径。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依组织类型分類的同种异体干细胞市场

  • 造血干细胞
    • 骨髓
    • 週边血
  • 间质干细胞
    • 脂肪组织
    • 骨髓
    • 脐带

第九章 同种异体干细胞市场：依应用领域划分

  • 循环系统
    • 心肌梗塞
    • 周边动脉疾病
  • 免疫疗法
    • CAR-T疗法
    • 树突细胞疗法
    • NK细胞疗法
  • 神经系统疾病
    • 阿兹海默症
    • 多发性硬化症
    • 帕金森氏症
    • 脊髓损伤
  • 整形外科
    • 骨再生
    • 软骨修復
    • 脊椎融合手术
  • 创伤治疗
    • 烧伤
    • 慢性伤口
    • 糖尿病足溃疡

第十章：异体干细胞市场：依来源划分

  • 脂肪组织
  • 骨髓
  • 週边血
  • 脐带

第十一章 同种异体干细胞市场：依产品类型划分

  • 冷冻保存
  • 冷冻干燥
  • 生的

第十二章 同种异体干细胞市场：依最终用户划分

  • 契约製造组织
  • 医院和诊所
  • 研究机构

第十三章：异体干细胞市场：依通路划分

  • 离线
  • 在线的

第十四章 异体干细胞市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 同种异体干细胞市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 异体干细胞市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国异体干细胞市场

第十八章 中国异体干细胞市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Allogene Therapeutics, Inc.
  • Athersys, Inc.
  • Celularity, Inc.
  • Cynata Therapeutics Limited
  • Fate Therapeutics, Inc.
  • Gamida Cell Ltd.
  • Mesoblast Limited
  • Osiris Therapeutics, Inc.
  • Pluristem Therapeutics, Inc.
  • TiGenix NV
Product Code: MRR-4969A8FF998A

The Allogeneic Stem Cells Market was valued at USD 393.14 million in 2025 and is projected to grow to USD 471.37 million in 2026, with a CAGR of 19.46%, reaching USD 1,365.40 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 393.14 million
Estimated Year [2026] USD 471.37 million
Forecast Year [2032] USD 1,365.40 million
CAGR (%) 19.46%

A focused orientation to the allogeneic stem cell landscape that frames clinical promise, manufacturing realities, and strategic decision levers for leaders

Allogeneic stem cell therapies, which leverage donor-derived cells to treat a range of indications, have moved from conceptual promise to tangible clinical momentum. Advances in cell sourcing, immune modulation, and scalable manufacturing have converged with evolving regulatory pathways to create renewed interest across biopharma, contract manufacturing, and clinical service providers. These therapies offer distinct advantages over autologous approaches, including the potential for off-the-shelf availability, standardized dosing, and economies of scale that can reduce per-treatment complexity.

Despite clear clinical opportunities, the pathway to broad adoption demands rigorous attention to supply chain integrity, cryopreservation techniques, and robust quality systems that ensure product consistency across batches and geographies. Stakeholders must reconcile scientific promise with operational realities, including donor screening, potency assays, and cold-chain logistics. As a result, strategic leaders increasingly prioritize investments in process development, modular manufacturing capacity, and regulatory engagement to reduce time-to-clinic and de-risk late-stage programs. The landscape rewards organizations that can align translational science with disciplined commercialization planning and adaptive manufacturing strategies.

Unearthing transformative shifts reshaping clinical pathways, manufacturing models, and commercialization strategies in allogeneic cell therapy

The allogeneic stem cell field is undergoing several concurrent shifts that are redefining value creation and competitive advantage. Clinically, multiplexed approaches and combinatorial regimens are expanding the therapeutic utility of donor-derived cells, with immune engineering and targeted delivery improving safety and efficacy profiles. This clinical evolution is paralleled by regulatory maturation: agencies are clarifying guidance around potency, comparability, and post-market surveillance, which reduces ambiguity for developers and accelerates program de-risking.

Operationally, manufacturing paradigms are shifting from centralized, bespoke facilities to hybrid networks where contract manufacturing organizations, regional centers, and flexible modular platforms coexist. This decentralization improves responsiveness to regional demand and mitigates single-point-of-failure risks in the supply chain. Moreover, improvements in cryopreservation and logistics, along with digital batch record systems and analytics, are raising the bar for reproducibility and lowering manufacturing variance. From a commercial perspective, payers and providers increasingly demand evidence of real-world durability and health-economic benefits, encouraging developers to integrate outcomes measurement into clinical programs early. Together, these shifts reward organizations that adopt end-to-end thinking, build cross-functional capabilities, and partner strategically across development, manufacturing, and care-delivery ecosystems.

Assessing the cumulative implications of United States tariff adjustments announced in 2025 on supply chains, sourcing strategies, and clinical program costs

The tariff adjustments implemented in 2025 have introduced new layers of complexity into the global logistics and sourcing calculus for allogeneic stem cell developers and their manufacturing partners. Tariff-induced cost pressures have primarily affected imported consumables, specialized reagents, and certain instrument categories critical to cell processing and cryogenic storage, prompting organizations to re-evaluate supplier portfolios and consider regionalizing procurement strategies where feasible. These shifts have made supply chain resilience a top boardroom priority, as delays or single-supplier dependencies can disrupt clinical timelines and patient access.

In response, many stakeholders accelerated supplier qualification programs, invested in local sourcing partnerships, and reconfigured inventory strategies to maintain continuity while managing incremental cost impacts. The tariffs also catalyzed conversations about vertical integration for select inputs, particularly where long-term supply certainty materially impacts clinical throughput. Regulatory filings and clinical operations teams have had to factor potential customs-related uncertainties into enrollment and manufacturing windows, and quality assurance functions have increased oversight on incoming material traceability. Overall, the 2025 tariff environment emphasizes the importance of flexible procurement, dual sourcing, and strategic inventory planning to preserve program momentum and protect patient-facing delivery schedules.

Extracting nuanced segmentation intelligence across tissue types, therapeutic applications, source origins, product formats, end-users, and distribution channels to guide portfolio prioritization

An effective segmentation framework illuminates where technical risk, clinical opportunity, and commercial fit intersect. Tissue-type differentiation distinguishes between hematopoietic stem cells, which are commonly derived from bone marrow and peripheral blood and serve hematologic and immune-focused indications, and mesenchymal stem cells, which originate from adipose tissue, bone marrow, and umbilical cord and are often pursued for their immunomodulatory and regenerative properties. These tissue-source relationships influence donor selection, manufacturing flow, and potency assay design, and they therefore deserve tailored development pathways.

Application-level segmentation further clarifies strategic focus areas. Cardiovascular indications such as myocardial infarction and peripheral arterial disease demand delivery systems and endpoints that differ substantially from immunotherapy programs, where CAR-T, dendritic cell, and natural killer cell approaches require specialized cell engineering and manufacturing controls. Neurological targets like Alzheimer's disease, multiple sclerosis, Parkinson's disease, and spinal cord injury create a distinct set of translational and regulatory challenges linked to the blood-brain barrier and long-term outcome measurement. In orthopedics, priorities center on bone regeneration, cartilage repair, and spine fusion, each requiring unique scaffolding and local delivery strategies. Wound healing programs that address burn wounds, chronic wounds, and diabetic foot ulcers emphasize local immunomodulation and matrix remodeling, with value often measured in healing time and functional recovery.

Source-based segmentation underscores that adipose tissue, bone marrow, peripheral blood, and umbilical cord each carry practical implications for donor logistics, cell yield, and regulatory categorization. Product-format segmentation differentiates cryopreserved, freeze-dried, and fresh offerings, with cryopreserved products offering logistical flexibility, freeze-dried approaches promising ambient stability in some emerging modalities, and fresh products necessitating tight coordination between manufacturing and site administration. End-user segmentation highlights differing procurement cycles and quality requirements among contract manufacturing organizations, hospitals and clinics, and research institutes, all of which inform commercial engagement models and service-level commitments. Finally, distribution-channel segmentation-comparing direct sales, distributors, and online channels-determines how value is captured across customer relationships, pricing strategies, and after-sales support. Together, these segmentation lenses enable leaders to prioritize investments that align technical feasibility with commercial pathways and operational capabilities.

Illuminating regional dynamics across the Americas, EMEA, and Asia-Pacific that influence regulatory approaches, manufacturing footprints, and adoption pathways for allogeneic therapies

Regional variation shapes the speed and structure of adoption for allogeneic stem cell therapies. In the Americas, regulatory frameworks increasingly emphasize streamlined pathways for regenerative medicines and advanced therapies, with strong clinical trial ecosystems and integrated hospital systems that can support early commercial launches and real-world evidence generation. These conditions favor sponsors who can coordinate multi-site studies and engage with payers on outcomes-based contracting and coverage models.

Europe, Middle East & Africa present a heterogeneous regulatory and reimbursement landscape where country-level pathways, health technology assessment processes, and decentralized procurement policies require tailored access strategies. Stakeholders must navigate differing standards for manufacturing certification, varying import requirements, and distinct approaches to value assessment. Asia-Pacific encompasses a wide spectrum of markets, from highly regulated jurisdictions with advanced clinical infrastructure to emerging markets that offer faster patient recruitment and cost-efficient manufacturing options. Across these regions, local partnerships and regulatory know-how are essential to bridging clinical evidence generation with market access, while regional manufacturing hubs can reduce logistics friction and support faster rollouts.

Strategic corporate behaviors and competitive archetypes shaping leadership in development, manufacturing, and logistical excellence for allogeneic cell programs

Companies active in the allogeneic stem cell space align into observable archetypes that reflect differing routes to scale and value capture. One archetype consists of vertically integrated developers that combine in-house research, process development, and clinical execution to protect intellectual property and maintain direct control over critical quality attributes. A second archetype includes specialized contract manufacturing organizations and service providers that offer scalable capacity, regulatory support, and technology transfer capabilities to multiple developers, thereby accelerating time-to-clinic for clients that prefer asset-light commercialization.

Other firms focus on supply chain and logistics excellence, building cold-chain networks, cryogenic storage solutions, and tracking systems that reduce loss and improve product viability across distances. Strategic partnerships and alliances are a common growth lever: co-development agreements, equity investments, and manufacturing partnerships help distribute risk and accelerate platform adoption. Competitive differentiation increasingly hinges on demonstrated manufacturing reproducibility, breadth of regulatory experience, and the ability to deliver clinical-grade evidence that supports payer discussions. Investors and corporate development teams prize organizations that can combine technical differentiation with scalable operations and validated route-to-market plans, and successful players tend to balance deep scientific expertise with rigorous process controls and market-oriented commercialization capabilities.

Practical and prioritized recommendations that industry leaders can implement to advance program robustness, supply resilience, regulatory readiness, and market adoption

First, integrate supply chain resilience into early development decisions by qualifying multiple suppliers for critical reagents, establishing regional procurement channels, and maintaining strategic inventory buffers to mitigate customs and tariff interruptions. Early dual sourcing and alternative-material strategies reduce single-provider risk and improve program continuity. Second, invest in modular and platform-based manufacturing approaches that enable rapid scale-up and provide flexibility to serve multiple indications from common production lines, thereby improving capital efficiency and reducing lead times to clinic.

Third, embed health-economic and outcomes evidence generation into clinical development plans from the outset to facilitate payer engagement and reimbursement negotiations. Demonstrating real-world durability and value can accelerate adoption in hospital systems. Fourth, pursue targeted partnerships with contract manufacturers, logistics specialists, and clinical networks that complement internal capabilities and expedite operational readiness. Fifth, prioritize robust analytical development and potency assays that align with regulatory expectations and enable comparability across batches and sites. Finally, cultivate cross-functional regulatory dialogues with authorities early and often to clarify expectations around post-market surveillance, potency metrics, and labeling, which reduces downstream uncertainty and accelerates patient access.

Transparent explanation of the interdisciplinary research approach used to develop the report's insights, combining primary engagement, secondary synthesis, and expert validation

The research methodology underpinning this analysis integrates primary stakeholder engagement, targeted literature synthesis, and iterative expert validation to ensure balanced, actionable findings. Primary inputs included structured interviews with clinical investigators, manufacturing leaders, supply chain specialists, and regulatory advisors, which provided real-world perspectives on operational constraints, clinical endpoints, and market access dynamics. These qualitative insights were triangulated with secondary sources spanning peer-reviewed literature, regulatory guidance documents, and technology white papers to contextualize trends and technical developments.

To enhance rigor, findings were validated through consultations with subject-matter experts and cross-checked against known regulatory milestones and public clinical progress. The methodology emphasized transparency about data provenance and uncertainty, documenting assumptions around supply chain behavior, regulatory interpretation, and clinical translation. Where necessary, sensitivity around proprietary commercial practices was respected, and industry anonymization techniques preserved the integrity of competitive insights while allowing readers to trust the reported strategic implications and operational recommendations.

A concise synthesis highlighting why integrated operational excellence, targeted clinical focus, and strategic partnerships are essential to realizing the potential of allogeneic stem cell therapies

The allogeneic stem cell sector stands at an inflection point where scientific advances and manufacturing innovations can translate into meaningful patient impact if matched with disciplined commercialization strategies. Clinical promise alone does not guarantee sustainable adoption; instead, success requires coupling translational rigor with reproducible manufacturing, resilient supply chains, and proactive payer engagement. Organizations that align these capabilities will be better positioned to navigate regulatory complexity and shorten the path from trial to routine use.

In closing, leaders should view the current environment as an opportunity to build enduring advantage by investing in modular manufacturing, robust analytical frameworks, and strategic partnerships that expand capacity and de-risk program execution. The pathway to commercial success depends on integrated planning across R&D, operations, and market access functions, and the organizations that execute on these coordinated priorities will set the standards for the next wave of allogeneic therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Allogeneic Stem Cells Market, by Tissue Type

  • 8.1. Hematopoietic Stem Cells
    • 8.1.1. Bone Marrow
    • 8.1.2. Peripheral Blood
  • 8.2. Mesenchymal Stem Cells
    • 8.2.1. Adipose Tissue
    • 8.2.2. Bone Marrow
    • 8.2.3. Umbilical Cord

9. Allogeneic Stem Cells Market, by Application

  • 9.1. Cardiovascular
    • 9.1.1. Myocardial Infarction
    • 9.1.2. Peripheral Arterial Disease
  • 9.2. Immunotherapy
    • 9.2.1. CAR-T Therapies
    • 9.2.2. Dendritic Cell Therapies
    • 9.2.3. NK Cell Therapies
  • 9.3. Neurological Disorders
    • 9.3.1. Alzheimers Disease
    • 9.3.2. Multiple Sclerosis
    • 9.3.3. Parkinsons Disease
    • 9.3.4. Spinal Cord Injury
  • 9.4. Orthopedics
    • 9.4.1. Bone Regeneration
    • 9.4.2. Cartilage Repair
    • 9.4.3. Spine Fusion
  • 9.5. Wound Healing
    • 9.5.1. Burn Wounds
    • 9.5.2. Chronic Wounds
    • 9.5.3. Diabetic Foot Ulcers

10. Allogeneic Stem Cells Market, by Source

  • 10.1. Adipose Tissue
  • 10.2. Bone Marrow
  • 10.3. Peripheral Blood
  • 10.4. Umbilical Cord

11. Allogeneic Stem Cells Market, by Product Type

  • 11.1. Cryopreserved
  • 11.2. Freeze Dried
  • 11.3. Fresh

12. Allogeneic Stem Cells Market, by End-User

  • 12.1. Contract Manufacturing Organizations
  • 12.2. Hospitals and Clinics
  • 12.3. Research Institutes

13. Allogeneic Stem Cells Market, by Distribution Channel

  • 13.1. Offline
  • 13.2. Online

14. Allogeneic Stem Cells Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Allogeneic Stem Cells Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Allogeneic Stem Cells Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Allogeneic Stem Cells Market

18. China Allogeneic Stem Cells Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Allogene Therapeutics, Inc.
  • 19.6. Athersys, Inc.
  • 19.7. Celularity, Inc.
  • 19.8. Cynata Therapeutics Limited
  • 19.9. Fate Therapeutics, Inc.
  • 19.10. Gamida Cell Ltd.
  • 19.11. Mesoblast Limited
  • 19.12. Osiris Therapeutics, Inc.
  • 19.13. Pluristem Therapeutics, Inc.
  • 19.14. TiGenix N.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ALLOGENEIC STEM CELLS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ALLOGENEIC STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ALLOGENEIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ALLOGENEIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CAR-T THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CAR-T THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CAR-T THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DENDRITIC CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DENDRITIC CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DENDRITIC CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NK CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NK CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NK CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ALZHEIMERS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ALZHEIMERS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ALZHEIMERS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PARKINSONS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PARKINSONS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PARKINSONS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE REGENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE REGENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE REGENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARTILAGE REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARTILAGE REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CARTILAGE REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINE FUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINE FUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SPINE FUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BURN WOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BURN WOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BURN WOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CHRONIC WOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CHRONIC WOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CHRONIC WOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIABETIC FOOT ULCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIABETIC FOOT ULCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DIABETIC FOOT ULCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CRYOPRESERVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CRYOPRESERVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CRYOPRESERVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FREEZE DRIED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FREEZE DRIED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FREEZE DRIED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FRESH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FRESH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY FRESH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL ALLOGENEIC STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. GCC ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. GCC ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. GCC ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 263. GCC ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 264. GCC ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. GCC ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 266. GCC ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. GCC ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 268. GCC ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 269. GCC ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 270. GCC ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 271. GCC ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. GCC ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 273. GCC ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 302. G7 ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 303. G7 ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. G7 ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 305. G7 ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 306. G7 ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 307. G7 ALLOGENEIC STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 308. G7 ALLOGENEIC STEM CELLS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 309. G7 ALLOGENEIC STEM CELLS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 310. G7 ALLOGENEIC STEM CELLS MARKET SIZE, BY ORTHOPEDICS, 2018-2032 (USD MILLION)
  • TABLE 311. G7 ALLOGENEIC STEM CELLS MARKET SIZE, BY WOUND HEALING, 2018-2032 (USD MILLION)
  • TABLE 312. G7 ALLOGENEIC STEM CELLS MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 313. G7 ALLOGENEIC STEM CELLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. G7 ALLOGENEIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 315. G7 ALLOGENEIC STEM CELLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 316. NATO ALLOGENEIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 317. NATO ALLOGENEIC STEM CELLS MARKET SIZE, BY TISSUE TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. NATO ALLOGENEIC STEM CELLS MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 319. NATO ALLOGENEIC STEM CELLS MARKET SIZE, BY MESENCHYMAL STEM CELLS, 2018-2032 (USD MILLION)
  • TABLE 320. NATO ALLOGENEIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 321. NATO